Stereotaxis Ord (STXS) Stock News

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular interventions, will release its Q1 2023 financial results on May 9, 2023, before U.S. markets open. A conference call is scheduled for the same day at 10 a.m. EST to discuss the results and corporate updates. Investors can access the call by dialing 800-715-9871 (US) or 1-646-307-1963 (International), using pass code 8054202. A replay of the call will be available for one month after the live event. Stereotaxis aims to enhance patient care through its robotic solutions, having served over 100,000 patients across various regions. This announcement emphasizes the company's commitment to transparency and engagement with its shareholders, as it prepares to disclose vital financial information.

Stereotaxis (NYSE: STXS) announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation (RMN) system since its introduction in late 2020. This advanced technology has been implemented at eight hospitals globally, including Banner University Medical Center and the National Institute of Cardiology in Poland. The Genesis RMN system enhances robotic precision and safety for cardiac ablation procedures, benefiting patients with complex cardiac diseases. With nearly two dozen robotic systems ordered, demand for the technology is growing. Stereotaxis continues to focus on providing innovative robotic solutions for minimally invasive interventions, having treated over 100,000 patients to date.

Stereotaxis (NYSE: STXS) has launched a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderdale, Florida, marking a significant advancement in cardiac care. The facility is the first in Florida and among the first in the U.S. to utilize the Genesis Robotic Magnetic Navigation System for treating complex heart rhythm disorders. This innovative technology aims to enhance patient safety and precision during cardiac ablation procedures, addressing the needs of millions affected by arrhythmias. The collaboration highlights Stereotaxis's commitment to advancing cardiac services and improving patient outcomes.

Stereotaxis (STXS) reported its financial results for Q4 and FY 2022, revealing a revenue decline to $7.3 million in Q4 from $8.2 million in Q4 2021. Full-year revenue dropped to $28.1 million from $35.0 million, attributed to hospital construction delays affecting system placements. The company recorded a net loss of $4.2 million in Q4 and an adjusted net loss of $7.8 million for the year. Despite these challenges, Stereotaxis aims for double-digit revenue growth in 2023, driven by a strong backlog of $14.8 million and expected regulatory approvals for new product innovations.

ST. LOUIS, Feb. 21, 2023 – Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced that Chairman and CEO David Fischel will speak at the Cowen 43rd Annual Health Care Conference. The presentation is scheduled for March 6, 2023, at 11:10 am ET, during a Fireside Discussion with Cowen's Managing Director, Josh Jennings. Fischel will also hold one-on-one meetings afterwards.

Fischel expressed enthusiasm about sharing Stereotaxis’ innovative technology and growth strategy with investors, highlighting its commitment to enhancing patient care and operational efficiency.

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular interventions, plans to release its financial results for Q4 and the full year 2022 on March 3, 2023, before U.S. market opening. A conference call will occur at 10 a.m. EST to discuss these results and corporate developments. Investors can participate via the dial-in number 800-715-9871 (U.S. and Canada) or 1-646-307-1963 (International) with passcode 6529896. The webcast will also be available on Stereotaxis' investor relations site. This event is crucial for assessing the company's performance and future outlook following its successful applications in over 100,000 procedures globally.

Stereotaxis (NYSE: STXS) has successfully treated nearly 500 patients using the Genesis Robotic Magnetic Navigation (RMN) system at Corewell Health's Fred & Lena Meijer Heart Center in Michigan. This marks the center as the first in the state to adopt this advanced robotic technology for cardiac ablation procedures aimed at treating complex heart arrhythmias. The Genesis system enhances precision and safety during procedures, crucial for improving patient outcomes. Stereotaxis continues to strengthen its partnership with Corewell Health to lead in arrhythmia care.

Stereotaxis (NYSE: STXS) has announced that Chairman and CEO David Fischel will participate in the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022. Fischel will present during a Fireside Discussion at 9:00 am ET, followed by a panel on The Future of Robotic Surgery at 10:00 am ET. He will also engage in one-on-one meetings throughout the day to discuss Stereotaxis’ innovative technology and growth strategies, emphasizing their commitment to improving patient care with robotic systems.

Stereotaxis reported $7.7 million in revenue for Q3 2022, down from $9.1 million year-over-year. The decline is attributed to reduced system revenue due to hospital construction delays affecting backlog conversion. Gross margin stood at 60%, with recurring revenue gross margin at 80%. Operating loss was $5.1 million, while adjusted net loss was $2.2 million, excluding stock compensation. The company maintains a cash balance of $32.4 million, with no debt, and a growing system backlog over $13 million, indicating potential for recovery and growth in the upcoming year.